LV11549B - Therapeutic peptide derivatives - Google Patents
Therapeutic peptide derivatives Download PDFInfo
- Publication number
- LV11549B LV11549B LVP-96-71A LV960071A LV11549B LV 11549 B LV11549 B LV 11549B LV 960071 A LV960071 A LV 960071A LV 11549 B LV11549 B LV 11549B
- Authority
- LV
- Latvia
- Prior art keywords
- peptide
- phe
- cys
- thr
- trp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Claims (12)
- LV 11549 PATENTA FORMULA 1. Peptida atvasinājums, kas satur: bioloģiski aktīvu peptida daļu, un 5 vismaz vienu aizvietotāju, kas pievienots pie minētās peptida daļas, kur minētais aizvietotājs ir izvēlēts no grupas, kas ietver savienojumus I, II un III, kur savienojums I ir:kur: R0 ir O, S vai NR5, kur R5 ir H vai (C,-C6)alkilgrupa; 15 katrs no R, un R2 neatkarīgi ir H, (CH2)mOR6 vai CH(OR7)CH2OR8, kur R6 ir H vai (C2-C;.)acilgrupa, un katrs no R7 and R8 neatkarīgi ir H, (C2-C7)acilgrupa vai C(Rg)(R10), kur katrs no R9 un R10 neatkarīgi ir H vai (C,-C6)alkilgrupa; vai katrs no R, un R2 ir grupa =CHCH2OR,,, kur aizvietotājā R, un R2 20 neatkarīgi R1t ir H vai (C2-C7)acilgrupa, un m ir vesels skaitlis starp 1 un 5, ieskaitot; un viens no R3 vai R4 ir (CH2)nR12 vai (CH2)nCH(OH)R12, kur R12 ir CO, CH2 vai S02, un n ir vesels skaitlis starp 1 un 5, ieskaitot; un atlikušais R3 vai R4 ir H, (C^Cgjhidroksialkilgrupa vai (C2-C7)acilgrupa; 25 un savienojums II ir: Rt3-0-CH2 30 R.4-0-CH2-C-(CH2)m-R,6-R17-(CH2)n-Rl8 r!5-o-ch2 35 kur: katrs no R,3, R,4 un R1S neatkarīgi ir H vai (C2-C24)acilgrupa; R16 ir NH vai nav vispār; 2 R17 ir CO, O vai nav vispār; R18 ir CO, CH2, S02 vai nav vispār; m ir vesels skaitlis starp 1 un 5, ieskaitot; n ir vesels skaitlis starp 0 un 5, ieskaitot; un savienojums III ir:kur: R)9 ir H, NH2, aromātiska funkcionāla grupa, OH, (C,-C6)hidroksialkilgrupa, H(R27)(R28), S03H vai nav vispār; kur katrs no R27 un R28 neatkarīgi ir H vai (Cļ-Cg) alkilgrupa; R^ ir O vai nav vispār; R21 ir (Cļ-Cgjalkilgrupa vai nav vispār; R22 ir N, 0, C vai CH; -R23- ir (C,-C6)alki(grupa vai nav vispār; R24 ir N, CH vai C; R25 ir NH, 0 vai nav vispār; R26 ir S02, CO, CH2 vai nav vispār; m ir vesels skaitlis starp 0 un 5, ieskaitot; n ir vesels skaitlis starp 0 un 5, ieskaitot; p ir vesels skaitlis starp 0 un 5, ieskaitot; q ir vesels skaitlis starp 0 un 5, ieskaitot; un kur minētā peptīda daļa ir pievienota pie katra no minētajiem aizvietotājiem ar CO-N, CH2-N vai S02*N saiti starp minēto aizvietotāju un minētās peptīda daļas N-gala vai sānu virknes slāpekļa atomu.
- 2. Peptīda atvasinājums saskaņā ar 1. punktu, kur minētais aizvietotājs ir savienojums II.
- 3. Peptīda atvasinājums saskaņā ar 2. punktu, kur minētais aizvietotājs ir (H0CH2)3C-NH-(CH)2-S02 vai (HOCH2)3C-CH2. 3 LV 11549
- 4. Peptīda atvasinājums saskaņā ar 1. punktu, kur minētais aizvietotājs ir savienojums III.
- 5. Peptīda atvasinājums saskaņā ar 4. punktu, kur minētais aizvietotājs ir viens no: HO(CH.,)2-N_N-(CH2)2S02- un HQ(CH2)2-N n-ch2-cq-
- 6. Peptīda atvasinājums saskaņā ar 1. punktu, kur minētā peptīda daļa ir izvēlēta no grupas, kurā ietilpst: somatostatīns, bombezīns, kalcitonīns, kalcitonīna gēnam atbilstošais peptīds (CGRP), amilīns, paratiroidais hormons (PTH), gastrīna atbrīvotājpeptīds (GRP), melanocītus stimulējošais hormons (MSH), adrenokortikotropais hormons (ACTH), paratiroīdajam hormonam radniecīgais peptīds (PTHrP), luteinizējošā hormona rilīzinghormons (LHRH), augšanas hormona atbrīvotājfaktors (GHRF), augšanas hormona atbrīvotājpeptīds (GHRP), holecistokinīns (CCK), glikagons, bradikinīns, glikagonam līdzīgais peptīds (GLP), gastrins, enkefalīns, neiromedīns, endotelīns, viela P, neiropeptids Υ (ΝΡΥ), peptīds ΥΥ (ΡΥΥ), vazoaktīvais zarnu peptīds (VIP), guanilīns, hipofīzes adenilātciklāzi aktivējošais polipeptīds (PACAP), beta-šūnu tropīns, adrenomedulīns un to atvasinājumi, fragmenti un analogi.
- 7. Peptīda atvasinājums saskaņā ar 6. punktu, kur minētā peptīda daļa ir somatostatīns vai tā atvasinājums, fragments vai analogs.
- 8. Peptīda atvasinājums saskaņā ar 7. punktu, kur minētais somatostatīna analogs ir viens no: H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2, H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH2 un H-D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2.
- 9. Peptīda atvasinājums saskaņā ar 6. punktu, kur minētā peptīda daļa ir bombezīns vai tā atvasinājums, fragments vai analogs. 4 I
- 10. Petīda atvasinājums saskaņā ar 1. punktu, kur minētais peptida atvasinājums ir viens no: HO(CH2)2-N^-(CH2)CO-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 un H0(CH2)2-N^N-(CH2)2S02-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2
- 11. Dimērs peptida atvasinājums, kas satur: divas bioloģiski aktīvas peptida daļas un vismaz vienu aizvietotāju, kas pievienots pie vienas no minētajām peptida daļām, kur minētais aizvietotājs ir viens no savienojumiem IV un V, kur savienojums IV ir:R0 ir O, S vai NR5, kur Rs ir H vai (C,-C6)alkilgrupa; katrs no R, un R2 neatkarīgi ir H, (CH2)mOR6 vai CH(OR7)CH2OR0, kur R6 ir H vai (C2-C7)acilgrupa, un katrs no R7 un R0 neatkarīgi ir H, (C2-C7)acilgrupa vai C(R9)(R10), kur katrs no R9 un R,0 neatkarīgi ir H vai (C,-C6)alkilgrupa; vai katrs no R, un R2 ir grupa =CHCH2OR,,, kur Rn aizvietotājos R, un R2 neatkarīgi ir H vai (C2-C7)acilgrupa, un m ir vesels skaitlis starp 1 un 5, ieskaitot; un katrs R3 vai R4 neatkarīgi ir (CH?)nRt2 vai (CH2)nCH(OH)R.2, kur R,2 ir CO, CH2 vai S02, un n ir vesels skaitlis starp 1 un 5, ieskaitot; un savienojums V ir: LV 11549 (CH2)m / \ ^19* ^20* ^21*^22' ^23 'R24'(CH2)p-R25-(CH2)q-R26 \ / (CH,)n kur: R,g ir S02, CO, CH2vai nav vispār; ir 0 vai nav vispār; R21 ir (C,-C6)alkilgrupa vai nav vispār; R22ir N, CH, O vai C; -R23- ir (C,-C6)alkilgrupa vai nav vispār; R24 ir N, CH vai C; R25 ir NH, 0 vai nav vispār; R26 ir S02, CO, CH2 vai nav vispār; m ir vesels skaitlis starp 0 un 5, ieskaitot; n ir vesels skaitlis starp 0 un 5, ieskaitot; p ir vesels skaitlis starp 0 un 5, ieskaitot; q ir vesels skaitlis starp 0 un 5, ieskaitot; un kur vismaz viena no minētajām peptīda daļām ir pievienota pie katra no minētajiem aizvietotājiem ar CO-N, CH2-N vai S02-N saiti starp minēto aizvietotāju un minētās peptīda daļas N-gala vai sānu virknes slāpekļa atomu.
- 12. Peptīda atvasinājums saskaņā ar 1. punktu, kas izmantojams slimības, īpaši vēža, ārstēšanai.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10419493A | 1993-08-09 | 1993-08-09 | |
| PCT/US1994/008875 WO1995004752A1 (en) | 1993-08-09 | 1994-08-08 | Therapeutic peptide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV11549A LV11549A (lv) | 1996-10-20 |
| LV11549B true LV11549B (en) | 1997-04-20 |
Family
ID=22299154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-96-71A LV11549B (en) | 1993-08-09 | 1996-03-08 | Therapeutic peptide derivatives |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5552520A (lv) |
| EP (3) | EP0788509B1 (lv) |
| JP (3) | JP3618750B2 (lv) |
| KR (1) | KR100325972B1 (lv) |
| CN (1) | CN1055700C (lv) |
| AT (3) | ATE284413T1 (lv) |
| AU (1) | AU689490B2 (lv) |
| CA (1) | CA2168113C (lv) |
| CZ (3) | CZ292586B6 (lv) |
| DE (3) | DE69432758T2 (lv) |
| DK (3) | DK0788509T3 (lv) |
| ES (3) | ES2196031T3 (lv) |
| FI (1) | FI960584A0 (lv) |
| GE (1) | GEP20002146B (lv) |
| HK (2) | HK1053314A1 (lv) |
| HU (1) | HU224350B1 (lv) |
| LT (1) | LT4078B (lv) |
| LV (1) | LV11549B (lv) |
| MD (1) | MD1591B2 (lv) |
| NZ (1) | NZ271238A (lv) |
| PL (1) | PL180612B1 (lv) |
| PT (2) | PT788509E (lv) |
| RO (1) | RO117259B1 (lv) |
| RU (1) | RU2133252C1 (lv) |
| SG (1) | SG75092A1 (lv) |
| SI (2) | SI0788509T1 (lv) |
| SK (1) | SK15096A3 (lv) |
| UA (1) | UA44707C2 (lv) |
| WO (1) | WO1995004752A1 (lv) |
| ZA (1) | ZA945966B (lv) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2774769B2 (ja) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| WO1996029343A1 (fr) * | 1995-03-20 | 1996-09-26 | Kyowa Hakko Kogyo Co., Ltd. | Nouveaux derives de calcitonine |
| US5824772A (en) * | 1995-04-04 | 1998-10-20 | Advanced Bioconcept, Inc. | Fluorescent somatostatin |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US6479457B2 (en) * | 1995-06-06 | 2002-11-12 | Kinerton Limited | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| US5830431A (en) * | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
| US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
| US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
| US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
| US7078413B2 (en) | 1996-04-19 | 2006-07-18 | Wisconsin Alumni Research Foundation | Compositions and methods of use for a bombesin peptide |
| US6492330B1 (en) * | 1996-08-16 | 2002-12-10 | National Institute Of Immunology | Antiangiogenic drugs |
| US5968903A (en) * | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
| US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| US6864234B1 (en) | 1999-06-25 | 2005-03-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Somatostatin agonists |
| BR0011919A (pt) * | 1999-06-25 | 2002-03-19 | Sod Conseils Rech Applic | Agonistas de somatostatina |
| EP1348444B1 (en) * | 1999-08-18 | 2006-04-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Sustained release formulation of a peptide complexed with a polymer |
| US7109166B1 (en) | 1999-08-18 | 2006-09-19 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Sustained release formulation of a peptide |
| IES990700A2 (en) | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
| AU2004200688B2 (en) * | 1999-08-18 | 2007-01-25 | Ipsen Pharma S.A.S. | Sustained release formulation of a peptide |
| DK1204429T3 (da) * | 1999-08-18 | 2004-03-08 | Sod Conseils Rech Applic | Præparat til forsinket frigivelse af et peptid |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US6316414B1 (en) | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
| MD2074G2 (ro) * | 2000-12-29 | 2003-06-30 | Юрий НИКИТИН | Procedeu şi instalaţie de captare a vaporilor de carburant la staţiile de alimentare cu petrol, condensator al vaporilor de carburant utilizat în instalaţia menţionată |
| ATE430162T1 (de) | 2001-03-06 | 2009-05-15 | Il Consorzio Ferrara Richerche | Verfahren zur modulation der proliferation von schilddrüsenkrebszellen |
| RU2263678C2 (ru) * | 2001-03-08 | 2005-11-10 | Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд | Антагонисты соматостатина |
| US20030229013A1 (en) * | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
| FR2833596B1 (fr) * | 2001-12-14 | 2005-02-18 | Aventis Pharma Sa | Procede de preparation de derives d'echinocandine |
| US20040171070A1 (en) * | 2002-05-20 | 2004-09-02 | Ramagauri Bhikhabhai | Peptide analysis using a solid support |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| US7229966B2 (en) | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| AU2003299722A1 (en) | 2002-12-17 | 2004-07-14 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7741431B2 (en) * | 2005-02-01 | 2010-06-22 | The United States Of America As Represented By The Secretary Of The Army | Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof |
| US20090220587A1 (en) * | 2005-02-01 | 2009-09-03 | United State Army | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands |
| US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
| CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
| US20110171191A1 (en) | 2008-06-12 | 2011-07-14 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| US10240138B2 (en) | 2008-06-12 | 2019-03-26 | Ipsen Bioinnovation Limited | Polypeptides that bind to and inhibit secretion from growth hormone secreting cells |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| US20120172650A1 (en) * | 2009-03-18 | 2012-07-05 | Laurence Katznelson | Use of somatostatin or an analogue thereof in combination with external radiation therapy |
| KR101823699B1 (ko) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
| EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
| PT2523653T (pt) | 2010-01-13 | 2018-06-28 | Ipsen Pharma Sas | Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina |
| CN102260352B (zh) * | 2010-05-28 | 2013-11-20 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
| EP2399931A1 (fr) * | 2010-06-22 | 2011-12-28 | Ipsen Pharma S.A.S. | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
| US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| AU2013337388B2 (en) | 2012-11-01 | 2018-08-02 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| KR102574993B1 (ko) | 2016-05-16 | 2023-09-06 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| CN108659100A (zh) * | 2017-03-28 | 2018-10-16 | 上海新生源医药集团有限公司 | 具有镇痛作用的多肽及其应用 |
| CA3116023A1 (en) | 2018-10-11 | 2020-04-16 | Intarcia Therapeutics, Inc. | Human amylin analog polypeptides and methods of use |
| KR20220017695A (ko) * | 2020-08-05 | 2022-02-14 | 주식회사 레미바이오 | 아스코르브산 유도체 및 이를 포함하는 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1246055A (en) * | 1980-03-24 | 1988-12-06 | Joseph H. Cort | N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs |
| DE3522638A1 (de) * | 1985-06-25 | 1987-01-08 | Diamalt Ag | Neue somatostatin-derivate |
| DE3614833A1 (de) | 1986-01-16 | 1987-07-23 | Hoechst Ag | Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| HU906341D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance |
| DK163689A (da) * | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
| DK375789A (da) | 1988-08-18 | 1990-02-19 | Syntex Inc | Peptidderivater |
| FR2638968B1 (fr) | 1988-11-11 | 1994-10-07 | Sandoz Sa | Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives |
| WO1991009837A1 (en) * | 1989-12-22 | 1991-07-11 | Commonwealth Scientific And Industrial Research Organisation | Amino acids, peptides or derivatives thereof coupled to fats |
| GB9209032D0 (en) * | 1992-04-25 | 1992-06-10 | Ciba Geigy Ag | New peptide derivatives |
-
1994
- 1994-08-08 KR KR1019960700664A patent/KR100325972B1/ko not_active IP Right Cessation
- 1994-08-08 SI SI9430451T patent/SI0788509T1/xx unknown
- 1994-08-08 EP EP94924590A patent/EP0788509B1/en not_active Expired - Lifetime
- 1994-08-08 GE GEAP19943038A patent/GEP20002146B/en unknown
- 1994-08-08 EP EP02026862A patent/EP1288223B1/en not_active Expired - Lifetime
- 1994-08-08 SI SI9420051A patent/SI9420051A/sl unknown
- 1994-08-08 WO PCT/US1994/008875 patent/WO1995004752A1/en active IP Right Grant
- 1994-08-08 ES ES94924590T patent/ES2196031T3/es not_active Expired - Lifetime
- 1994-08-08 CA CA002168113A patent/CA2168113C/en not_active Expired - Fee Related
- 1994-08-08 DE DE69432758T patent/DE69432758T2/de not_active Expired - Lifetime
- 1994-08-08 DK DK94924590T patent/DK0788509T3/da active
- 1994-08-08 HU HU9600281A patent/HU224350B1/hu not_active IP Right Cessation
- 1994-08-08 UA UA96020456A patent/UA44707C2/uk unknown
- 1994-08-08 RU RU96104340A patent/RU2133252C1/ru not_active IP Right Cessation
- 1994-08-08 EP EP02026863A patent/EP1288224B1/en not_active Expired - Lifetime
- 1994-08-08 PT PT94924590T patent/PT788509E/pt unknown
- 1994-08-08 PT PT02026862T patent/PT1288223E/pt unknown
- 1994-08-08 ES ES02026862T patent/ES2229045T3/es not_active Expired - Lifetime
- 1994-08-08 NZ NZ271238A patent/NZ271238A/en not_active IP Right Cessation
- 1994-08-08 DE DE69434181T patent/DE69434181T2/de not_active Expired - Lifetime
- 1994-08-08 CN CN94193717A patent/CN1055700C/zh not_active Expired - Fee Related
- 1994-08-08 AT AT02026862T patent/ATE284413T1/de not_active IP Right Cessation
- 1994-08-08 PL PL94312989A patent/PL180612B1/pl not_active IP Right Cessation
- 1994-08-08 AT AT94924590T patent/ATE241643T1/de not_active IP Right Cessation
- 1994-08-08 SG SG1996005779A patent/SG75092A1/en unknown
- 1994-08-08 DK DK02026863T patent/DK1288224T3/da active
- 1994-08-08 AT AT02026863T patent/ATE399177T1/de not_active IP Right Cessation
- 1994-08-08 MD MD96-0137A patent/MD1591B2/ro unknown
- 1994-08-08 RO RO96-00225A patent/RO117259B1/ro unknown
- 1994-08-08 DE DE69435105T patent/DE69435105D1/de not_active Expired - Lifetime
- 1994-08-08 AU AU74819/94A patent/AU689490B2/en not_active Ceased
- 1994-08-08 CZ CZ1996390A patent/CZ292586B6/cs not_active IP Right Cessation
- 1994-08-08 DK DK02026862T patent/DK1288223T3/da active
- 1994-08-08 SK SK150-96A patent/SK15096A3/sk unknown
- 1994-08-08 JP JP50654195A patent/JP3618750B2/ja not_active Expired - Lifetime
- 1994-08-08 ES ES02026863T patent/ES2309131T3/es not_active Expired - Lifetime
- 1994-08-09 ZA ZA945966A patent/ZA945966B/xx unknown
- 1994-08-09 US US08/287,957 patent/US5552520A/en not_active Expired - Lifetime
-
1996
- 1996-02-08 FI FI960584A patent/FI960584A0/fi not_active Application Discontinuation
- 1996-03-06 LT LT96-025A patent/LT4078B/lt not_active IP Right Cessation
- 1996-03-08 LV LVP-96-71A patent/LV11549B/en unknown
-
2000
- 2000-03-22 CZ CZ20001033A patent/CZ289552B6/cs not_active IP Right Cessation
- 2000-03-22 CZ CZ20001032A patent/CZ289590B6/cs not_active IP Right Cessation
-
2003
- 2003-08-04 HK HK03105592A patent/HK1053314A1/xx not_active IP Right Cessation
- 2003-08-04 HK HK03105591A patent/HK1053313A1/xx not_active IP Right Cessation
-
2004
- 2004-08-12 JP JP2004235535A patent/JP3785179B2/ja not_active Expired - Lifetime
- 2004-08-12 JP JP2004235503A patent/JP3869439B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5552520A (en) | Therapeutic peptide derivatives | |
| HUT62604A (en) | Process for producing peptides for treating tissue proliferation and pharmaceutical compositions comprising same | |
| HU205771B (en) | Process for producing irreversible peptide ligands for bombesin receptors and process for producing pharmaceutical compositions comprising such peptides as active ingredient | |
| EP0588873B1 (en) | Treatment of liver cancer | |
| AU8311191A (en) | Bombesin antagonists | |
| AU630715B2 (en) | Irreversible bombesin antagonists | |
| MXPA00000455A (en) | Therapeutic peptide derivatives | |
| RU2088592C1 (ru) | Терапевтические пептиды или их фармацевтически приемлемые соли | |
| JP3743794B2 (ja) | ボンベシン類似体 |